Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
US 'strikes price cut deal' with Swiss pharma giants
The deal is expected to be made public on Friday, Bloomberg reports, citing sources close to the matter. According to the news agency, the agreement could be part of a broader announcement involving other pharmaceutical groups, but the details have…
Pharma Makes Billions From Cancer Drugs. Do They Work?
Never miss an episode. Follow The Big Take daily podcast today. Treating cancer is a massive business. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry, more than the obesity drug…
Big Pharma Is Making Mexico Sick. Medicine and Supply Shortages Are Rampant.
Truthout's December fundraiser is our most important of the year and will determine the scale of work we will be able to do in 2026. Please support us with a tax-deductible donation today. The U.S. has the highest medical and health care costs in…
Sun Pharma shares drop after U.S. FDA inspection
Shares of Sun Pharmaceutical Industries closed 2.77% lower on Thursday (December 18, 2025) at ₹1,745.35 apiece on the BSE after the U.S. Food and Drug Administration (U.S. FDA) classified the company's facility in Baska, Gujarat, as Official…
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer December 18, 2025 8:30 AM EST Julie Rathbun - Head of Investor Relations Mark Litton - President, CEO & Director Javier San…
Pharmalittle: We're reading about Lilly's obesity pill, pharma deals with Trump, and much more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual…
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders bought 4,033 put options on the stock. This represents an increase of 114% compared to the typical daily volume…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Down 5.3% - Time to Sell?
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) dropped 5.3% during trading on Thursday. The company traded as low as $74.58 and last traded at $74.58. Approximately 250 shares traded hands during trading, a decline of 67% from the average…
George Osborne has a new job in tech, and it doesn't bode well for Britain | Chris Stokel-Walker
George Osborne getting a new job isn't exactly news. Since leaving frontline politics, the former chancellor has served as the chair of the Northern Powerhouse Partnership, edited (not entirely successfully) the Evening Standard, advised asset…
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 69,582 shares of the company's stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $38.36, for a total value of…
Sensex down 78 points on weak global trends
Benchmark stock indices Sensex and Nifty declined for the fourth straight day on Thursday amid uncertainty over a trade deal and a muted trend in global markets. Logging its fourth day of decline, the 30-share BSE Sensex dropped by 77.84 points or…
Merck stock upgraded at BMO Capital Markets (MRK:NYSE)
BMO Capital Markets upgraded to Outperform from Market Perform and raised its price target to $130 from $82 on Thursday, arguing that the pharma giant is well positioned to face the upcoming patent cliff for its blockbuster cancer drug Keytruda.
Stock markets decline for fourth day on weak global trends, trade deal uncertainty
Benchmark stock indices Sensex and Nifty closed lower for the fourth consecutive day on Thursday (December 18, 2025) amid a muted trend in global markets and uncertainty over a trade deal with the U.S. Falling for the fourth day, the 30-share BSE…
![albertvilella.substack.com - Albert - Is Recursion Pharma up for acquisition? [COPY] JPM25: Recursion $RXRX](https://substackcdn.com/image/fetch/$s_!2flG!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F195acbd3-cf7d-47c1-8927-c76691cf71c8_1000x671.jpeg)
Is Recursion Pharma up for acquisition? [COPY] JPM25: Recursion $RXRX
Below is the piece I wrote a year ago for JPM Healthcare on Recursion Pharma. Back then the stock was trading at $6-8 per share, now recently bounced back from $4 to $4.75. I think there is now a good chance of the company being acquired at a good…
Receive a Daily briefing on Pharma Industry News
Get Started